ClinicalTrials.gg
Active, not recruitingNCT04861259COMMUTE-aUpdated Oct 30, 2026Results posted

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

A Phase 3 interventional study of Crovalimab in Atypical Hemolytic Uremic Syndrome, sponsored by Hoffmann-La Roche. Active, not recruiting at 41 sites in 16 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Updated Oct 30, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
83
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Atypical Hemolytic Uremic Syndrome with a site in United States — 3 open to participants now, 5 under way, 2 of them phase 3. Atypical Hemolytic Uremic Syndrome · United States.

Enrollment
Largest of 13
83 · median 34
Started
2021
with 1 other
Phase 3
6 of 20
none open now
Registered
16th of 20
by date
Lead sponsor
2 of 20
Hoffmann-La Roche

Among the 20 studies in Atypical Hemolytic Uremic Syndrome with a site in United States, this one has the largest enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2021, is one of 6 in phase 3, and was the 16th registered.

Atypical Hemolytic Uremic Syndrome

45 studies on the registry are indexed under Atypical Hemolytic Uremic Syndrome; 14 are open to participants now.

Browse Atypical Hemolytic Uremic Syndrome studies →

Open to participants now

3 of the 20 studies in Atypical Hemolytic Uremic Syndrome with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Atypical Hemolytic Uremic Syndrome studies recruiting now, 10 (83%) set no upper age limit and none (0%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Atypical Hemolytic Uremic Syndrome with a site in United States, or all of them as a file.
02

Study summary

This study aims to evaluate the efficacy and safety of crovalimab in adult and adolescent participants with aHUS.

03

Conditions studied

  • Atypical Hemolytic Uremic Syndrome
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight >= 40 kg at screening.
  • Vaccination against Neisseria meningitidis serotypes A, C, W, and Y; vaccination against serotypes B, according to national vaccination recommendations.
  • Vaccination against Haemophilus influenzae type B and Streptococcus pneumoniae, according to national vaccination recommendations.
  • For participants continuing to receive other therapies concomitantly with crovalimab (e.g., , , mammalian target of rapamycin inhibitor (mTORi) , or calcineurin inhibitors): stable dose for >=28 days prior to screening and up to the first crovalimab administration.
  • For female participants of : an agreement to remain abstinent or use .
  • Female participants of childbearing potential must have a negative serum pregnancy test result within 7 days prior to initiation of crovalimab.
  • Participants with a prior kidney transplant are eligible if they have a known history of complement-mediated aHUS prior to the kidney transplant.
  • Onset of initial TMA presentation within 28 days prior to the first dose of crovalimab (for Naive Cohort only).
  • Documented treatment with either eculizumab or ravulizumab (for Switch Cohort only).
  • Clinical evidence of response to a C5 inhibitor (for Switch Cohort only).
  • Known C5 polymorphism (for C5 SNP Cohort only).
  • Poorly controlled TMA following treatment with another C5 inhibitor (for C5 SNP Cohort only).

Exclusion criteria

Exclusion Criteria:

  • TMA associated with non-aHUS related renal disease.
  • Positive direct Coombs test.
  • Chronic dialysis within 90 days prior to first crovalimab administration and/or end stage renal disease.
  • Identified drug exposure-related TMA.
  • Presence or history of a condition that could trigger TMA, such as , bone marrow or organ transplant (other than kidney transplant) or disease.
  • History of a kidney disease, other than aHUS.
  • History of Neisseria meningitidis infection within 6 months of study enrollment.
  • Known or suspected immune deficiency (e.g., history of frequent recurrent infections).
  • Positive (HIV) test.
  • Active systemic bacterial, viral, or fungal infection within 14 days before first crovalimab administration
  • Presence of fever (>= 38°C)
  • Multi-system organ dysfunction or failure.
  • Recent intravenous immunoglobulin (IVIg) treatment.
  • Pregnant or breastfeeding or intending to become pregnant.
  • Participation in another interventional treatment study with an agent or use of any experimental therapy within 28 days of screening or within five half lives of that investigational product, whichever is greater.
  • Recent use of tranexamic acid.
  • Current or previous treatment with a complement inhibitor (for Naive Cohort only).
  • First initiation of plasma exchange/plasma infusions (PE/PI) should not be more than 28 days prior to first crovalimab administration (for Naive Cohort only).
  • Last PE/PI completed less than 2 hours prior to first crovalimab administration (for Naive Chorot only).
  • Receiving PE/PI within 8 weeks of the first crovalimab administration (Switch Cohort only).
  • Positive for active and C infection (HBV/) (for Switch Cohort and C5 SNP Cohort participants who recently received C5 inhibitor treatment).
  • Cryoglobulinemia at screening (for Switch Cohort and C5 SNP Cohort participants who recently received C5 inhibitor treatment).
  • Diagnosis of condition leading to non-aHUS TMA: Thrombotic Thrombocytopenic Purpura (TTP), Shiga Toxin producing Escherichia Coli (STEC)
  • TMA, Pneumococcal HUS, TMA secondary to cobalamin C defect and TMA related to a known DGKE nephropathy.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
83 participants (actual)

Study arms

  • Experimental
    Crovalimab

    Participants will be enrolled in three cohorts: \[1\] Naive Cohort - participants who have not been previously treated with complement inhibitor therapy; \[2\] Switch Cohort - participants who switch to crovalimab from another Complement Component 5 (C5) inhibitor and \[3\] C5 Single Nucleotide Polymorphism (C5 inhibitor) Cohort - participants with documented C5 polymorphism.

    Drug: Crovalimab

Interventions

  • Crovalimab will be administered at a dose of 1000 milligrams (mg) intravenous (IV) (for participants with body weight at least 40 (\>=) and up to 100 kilograms (kg) or 1500 mg IV (for participants with body weight \>=100kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg subcutaneously (SC). On Week 5 and every 4 weeks (Q4W) thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight \>= 40kg to \<100kg) or 1020 mg SC (for participants with body weight \>=100kg).

06

What researchers measure

Primary outcomes

  1. Naive Cohort: Percentage of Participants With Complete Thrombotic Microangiopathy Response (cTMAr) Anytime From Baseline to Week 25

    cTMAr was defined by meeting all of the following criteria at two separate assessments, obtained at least 4 weeks (a minimum of 26 days) apart, and any measurement in between: platelet count ≥ lower limit of normal (LLN); lactate dehydrogenase (LDH) ≤ upper limit of normal (ULN); and ≥25% decrease in serum creatinine from baseline. Participants with normalized creatinine (i.e., LLN ≤ creatinine ≤ ULN) at baseline were excluded from analysis. Percentage has been rounded off.

    Time frame: Baseline up to Week 25 (after 24 weeks on treatment)

Secondary outcomes

  1. Naive and Switch Cohorts: Percentage of Participants Requiring Dialysis at Baseline and at Week 25 Who Completed 24 Weeks of Treatment

    Participants were considered to be on dialysis at baseline or at Week 25 if dialysis occurred within 5 days prior to the first crovalimab administration or prior to the end date of the primary treatment period, respectively. The percentage of participants who required dialysis at baseline and Week 25 has been reported here. Percentages have been rounded off.

    Time frame: Baseline up to Week 25 (after 24 weeks on treatment)

  2. Naïve and Switch Cohorts: Percentage of Participants With Change From Baseline to Week 25 (After 24 Weeks on Treatment) on Dialysis Status (Yes/No)

    Participants were considered as being on dialysis at baseline or at Week 25 if dialysis occurred within 5 days prior to the first crovalimab administration or prior to the end date of the primary treatment period, respectively. Participants who were on dialysis at any time point from baseline to Week 25 were classified as "Initiated dialysis at any time point ". Participants who remained dialysis-free throughout the primary treatment period were classified as "Remained dialysis free throughout". Participants who were on dialysis at Week 25 were classified as "Remained on dialysis". Participants who discontinued dialysis at Week 25 were classified as "Discontinued dialysis. Percentages have been rounded off.

    Time frame: From baseline up to Week 25

  3. Naive and Switch Cohorts: Observed Values of Estimated Glomerular Filtration Rate (eGFR), as Calculated From Central Serum Creatinine

    GFR is an index of kidney function that describes the flow rate of filtered fluid through the kidneys. It was categorized according to chronic kidney disease (CKD) staging criteria. eGFR was calculated using the creatinine-based bedside Schwartz equation for adolescents and 2009 CKD-Epidemiology Collaboration (EPI) creatinine equation for adults. Formula for creatinine-based bedside Schwartz equation was eGFR (milliliters per minute per 1.73 square meter \[mL/min/1.73 m\^2\])=0.413\*(height \[ht\]/serum creatinine \[sCr\]), if height is expressed in centimeters, or 41.3\*(ht/sCr), if height is expressed in meters, and formula for 2009 CKD-EPI creatinine equation was eGFR (mL/min/1.73 m\^2)= 141\*min(sCr /κ,1)\^α\*max(sCr/κ,1)\^ -1.209\*0.993\^AGE\[\*1.018 if female\]\[\*1.159 if black\], κ was 0.7 for females and 0.9 for males, α was -0.329 for females and -0.411 for males, min indicated the minimum of sCr/κ or 1, and max indicated the maximum of sCr/κ or 1.

    Time frame: Baseline, Weeks 2, 3, 4, 5, 7, 9, 13, 17, 21, and 25

  4. Naive and Switch Cohorts: Change From Baseline up to Week 25 in eGFR, as Calculated From Central Serum Creatinine

    GFR is an index of kidney function that describes the flow rate of filtered fluid through the kidneys. It was categorized according to CKD staging criteria. eGFR was calculated using the creatinine-based bedside Schwartz equation for adolescents and 2009 CKD- EPI creatinine equation for adults. Formula for creatinine-based bedside Schwartz equation was eGFR (mL/min/1.73 m\^2)=0.413\*(ht/sCr), if height is expressed in centimeters, or 41.3\*(ht/sCr), if height is expressed in meters, and formula for 2009 CKD-EPI creatinine equation was eGFR (mL/min/1.73 m\^2)= 141\*min(sCr /κ,1)\^α\*max(sCr/κ,1)\^ -1.209\*0.993\^AGE\[\*1.018 if female\]\[\*1.159 if black\], κ was 0.7 for females and 0.9 for males, α was -0.329 for females and -0.411 for males, min indicated the minimum of sCr/κ or 1, and max indicated the maximum of sCr/κ or 1.

    Time frame: Baseline, Weeks 2, 3, 4, 5, 7, 9, 13, 17, 21, and 25

  5. Naive and Switch Cohorts: Percentage of Participants With Change in Chronic Kidney Disease (CKD) Stage From Baseline to Week 25, as Assessed Based on eGFR Calculated From Central Serum Creatinine

    CKD stage assessed using eGFR, classified per National Kidney Foundation CKD staging criteria: grade 1 (≥90 mL/min/1.73 m²; normal or high), grade 2 (60-89 mL/min/1.73 m²; mildly decreased), grade 3a (45-59 mL/min/1.73 m²; mildly to moderately decreased), grade 3b (30-44 mL/min/1.73 m²; moderately to severely decreased), grade 4 (15-29 mL/min/1.73 m²; severely decreased), grade 5 (\<15 mL/min/1.73 m²; kidney failure). Change in CKD stage from baseline to Week 25, categorized as improved (participants who improved in CKD stage from baseline to Week 25 were based on number of participants who completed 24 weeks \& were not stage 1 at baseline), stable (no change), or worsened (CKD stage 1-4 at baseline) among participants who completed 24 weeks of treatment. Percentages rounded off.

    Time frame: Baseline up to Week 25 (after 24 weeks on treatment)

  6. Naive and Switch Cohorts: Observed Value of Platelet Count

    Time frame: Baseline and Week 25

  7. Naive and Switch Cohorts: Observed Value of Lactate Dehydrogenase (LDH)

    Time frame: Baseline and Week 25

  8. Naive and Switch Cohorts: Observed Value of Hemoglobin

    Time frame: Baseline and Week 25

  9. Naive and Switch Cohorts: Change From Baseline in Platelet Count at Week 25

    Time frame: Baseline and Week 25

  10. Naive and Switch Cohorts: Change From Baseline in LDH at Week 25

    Time frame: Baseline and Week 25

  11. Naive and Switch Cohorts: Change From Baseline in Hemoglobin at Week 25

    Time frame: Baseline and Week 25

  12. Naive and Switch Cohorts: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 25

    Fatigue was measured by the FACIT-Fatigue questionnaire in adult participants only (≥18 years at baseline). It consists of 13 items that assess fatigue using a 7-day recall period. Items are scored on a 0= 'Not at all' to 4= 'Very much so' response scale. Relevant items are reverse scored, and all items are summed to create total score where higher scores are indicative of better functioning (i.e., less fatigue). The FACIT-Fatigue total score ranges from 0 to 52, with higher scores representing less fatigue; therefore, an increase in score represents an improvement in fatigue. Only categories with non-zero values were reported.

    Time frame: Baseline, Weeks 1 (Day 1), 2, 5, 9, 17, and 25

  13. Naive Cohort: Percentage of Participants With Platelet Count ≥ LLN at Two Separate Assessments, Obtained at Least 4 Weeks Apart (Minimum of 26 Days), by Week 25 (After 24 Weeks on Treatment)

    This event was confirmed at two separate assessments obtained at least 4 weeks (a minimum of 26 days) apart and any measurement in between. Percentages are rounded off.

    Time frame: Baseline up to Week 25 (after 24 weeks on treatment)

  14. Naive Cohort: Percentage of Participants With LDH ≤ Upper Limit of Normal (ULN) at Two Separate Assessments, Obtained at Least 4 Weeks Apart (Minimum of 26 Days), by Week 25 (After 24 Weeks on Treatment)

    Percentages are rounded off.

    Time frame: From baseline through Week 25 (after 24 weeks on treatment)

  15. Naive Cohort: Percentage of Participants With ≥25% Decrease in Serum Creatinine From Baseline at Two Separate Assessments, Obtained at Least 4 Weeks Apart (Minimum of 26 Days), by Week 25 (After 24 Weeks on Treatment)

    Percentages are rounded off.

    Time frame: Baseline up to Week 25 (after 24 weeks on treatment)

  16. Naive Cohort: Time to Complete Thrombotic Microangiopathy Response (cTMAr)

    cTMAr was defined by meeting all of the following criteria at two separate assessments, obtained at least 4 weeks (a minimum of 26 days) apart, and any measurement in between: Platelet count ≥ LLN; LDH ≤ ULN; and ≥ 25% decrease in serum creatinine from baseline and \> ULN. Kaplan-Meier (K-M) method was used to estimate median time to cTMAr. Data for participants who did not reach cTMAr during the primary treatment period were censored at the date of their last visit when cTMAr was assessed during the primary treatment period or prior to the treatment discontinuation, whichever was earlier. Data for participants who received a prohibited therapy during the primary treatment period were censored at the date of the first received prohibited therapy during the primary treatment period or prior to the treatment discontinuation, whichever was earlier.

    Time frame: From baseline up to Week 25

  17. Naive Cohort: Duration of cTMAr

    cTMAr was defined by meeting following criteria at 2 separate assessments, obtained at least 4 weeks (minimum of 26 days) apart \& any measurement in between: Platelet count ≥ LLN; LDH ≤ ULN; \& ≥25% decrease in serum creatinine from baseline \& \> ULN. Duration of cTMAr was calculated as time from start of cTMAr to end of cTMAr. End of cTMAr was when all above-mentioned criteria were met during same visit \& confirmed at an assessment that took place at least 4 weeks (minimum of 26 days) later. K-M method was used to estimate median duration of cTMAr. Data for participants with no observed end of cTMAr at clinical cutoff date (CCOD) were censored at the date of their last visit when cTMAr was assessed before CCOD or before treatment discontinuation, whichever was earlier. Data for participants who received a prohibited therapy prior to the CCOD were censored at date of the first received prohibited therapy or prior to the treatment discontinuation, whichever was earlier.

    Time frame: From baseline up to primary CCOD (up to 207 weeks)

  18. Naive Cohort: Percentage of Participants With cTMAr Ongoing at Week 25

    cTMAr at Week 25 was defined by meeting all of the three cTMAr criteria at Week 25: Platelet count ≥ LLN; LDH ≤ ULN; and ≥ 25% decrease in serum creatinine from baseline and \> ULN. Percentage has been rounded off.

    Time frame: At Week 25

  19. Switch Cohort: Percentage of Participants With Maintained Thrombotic Microangiopathy Control (mTMAc) From Baseline Through Week 25 (After 24 Weeks on Treatment)

    mTMAc was considered not maintained if all of the following criteria were met during one of the visits between baseline and Week 25, and were confirmed at an assessment that took place at least 4 weeks (a minimum of 26 days) later: Platelet count \< LLN; LDH \> ULN; and 25% increase in serum creatinine from baseline and \> ULN.

    Time frame: From baseline through Week 25 (After 24 weeks on treatment)

  20. All Cohorts: Number of Participants With AEs

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: Up to approximately 8 years

  21. All Cohorts: Number of Participants With Injection-Site Reactions, Infusion-Related Reactions, Hypersensitivity, Malignant Hypertension and Infections

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Infusion-related and injection-site reactions were adverse events that occured during or within 24 hours after crovalimab administration and were judged to be related to study drug infusion or injection.

    Time frame: Up to approximately 8 years

  22. All Cohorts: Number of Participants With AE Leading to Study Drug Discontinuation

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: Up to approximately 8 years

  23. Switch Cohort: Number of Participants With Clinical Manifestations of Drug-target-drug Complexes (DTDCs)

    In this study, the risk of DTDC is relevant only to participants who might switch to crovalimab from eculizumab or ravulizumab treatment at study enrollment, and to participants who discontinued crovalimab and switch to eculizumab or ravulizumab. Type III hypersensitivity may occur due to the transient formation of DTDCs made of eculizumab or ravulizumab, crovalimab, and C5 in participants switching from eculizumab or ravulizumab to crovalimab.

    Time frame: Up to approximately 8 years

  24. All Cohorts: Crovalimab Serum Concentration

    Time frame: Up to approximately 8 years

  25. All Cohorts: Percentage of Participants With Anti-Drug Antibodies (ADAs) to Crovalimab

    Participants will be considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following study drug exposure (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples is at least 4-fold greater than the titer of the baseline sample (treatment-enhanced ADA response).

    Time frame: Up to approximately 8 years

  26. All Cohorts: Observed Value of Complement Activity (CH50) Over Time, as Measured by Liposome Immunoassay (LIA)

    Time frame: Up to approximately 8 years

  27. All Cohorts: Change From Baseline in CH50 Over Time, as Measured by LIA

    Time frame: Up to approximately 8 years

  28. All Cohorts: Observed Value of Free Complement Component 5 (C5) Concentrations in Crovalimab-treated Participants

    Time frame: Up to approximately 8 years

  29. All Cohorts: Change From Baseline in Free C5 Concentrations Over Time in Crovalimab-treated Participants

    Time frame: Up to approximately 8 years

  30. All Cohorts: Observed Value of Total C5 Concentrations in Crovalimab-treated Participants

    Time frame: Up to approximately 8 years

  31. All Cohorts: Change From Baseline in Total C5 Concentrations in Crovalimab-treated Participants

    Time frame: Up to approximately 8 years

07

Results

Posted Oct 30, 2026

Participant flow

A total of 83 participants were enrolled at 42 investigative sites across 16 countries. Participants were planned to be enrolled in 3 parallel cohorts, based on their previous exposure \& response to complement inhibitor therapy: Naïve, Switch, \& component 5 (C5) single nucleotide polymorphism (SNP) (documented C5 polymorphism) cohorts.

Primary Treatment Period (24 Weeks)
Participant flow — Primary Treatment Period (24 Weeks)
MilestoneCrovalimab Naive CohortCrovalimab Switch CohortCrovalimab C5 SNP Cohort
Started41411
Efficacy evaluable population37410
Completed34390
Not completed721
Withdrew: Death100
Withdrew: Withdrawal by subject110
Withdrew: Ahus misdiagnosis001
Withdrew: Entered sfu510
Crovalimab Continuation Period
Participant flow — Crovalimab Continuation Period
MilestoneCrovalimab Naive CohortCrovalimab Switch CohortCrovalimab C5 SNP Cohort
Started27360
Completed000
Not completed27360
Withdrew: Death100
Withdrew: Lost to follow-up010
Withdrew: Entered sfu300
Withdrew: Ongoing study treatment23350
Safety Follow-up Period
Participant flow — Safety Follow-up Period
MilestoneCrovalimab Naive CohortCrovalimab Switch CohortCrovalimab C5 SNP Cohort
Started1341
Completed711
Not completed630
Withdrew: Ongoing in study220
Withdrew: Death100
Withdrew: Withdrawal by subject200
Withdrew: Lost to follow-up100
Withdrew: Other010

Outcome measures

PrimaryNaive Cohort: Percentage of Participants With Complete Thrombotic Microangiopathy Response (cTMAr) Anytime From Baseline to Week 25

cTMAr was defined by meeting all of the following criteria at two separate assessments, obtained at least 4 weeks (a minimum of 26 days) apart, and any measurement in between: platelet count ≥ lower limit of normal (LLN); lactate dehydrogenase (LDH) ≤ upper limit of normal (ULN); and ≥25% decrease in serum creatinine from baseline. Participants with normalized creatinine (i.e., LLN ≤ creatinine ≤ ULN) at baseline were excluded from analysis. Percentage has been rounded off.

Time frame:
Baseline up to Week 25 (after 24 weeks on treatment)
Reported as:
Number · percentage of participants
Naive Cohort: Percentage of Participants With Complete Thrombotic Microangiopathy Response (cTMAr) Anytime From Baseline to Week 25
percentage of participantsCrovalimab Naive Cohort
Naive Cohort: Percentage of Participants With Complete Thrombotic Microangiopathy Response (cTMAr) Anytime From Baseline to Week 2559.5 (43.49 to 73.65)
SecondaryNaive and Switch Cohorts: Percentage of Participants Requiring Dialysis at Baseline and at Week 25 Who Completed 24 Weeks of Treatment

Participants were considered to be on dialysis at baseline or at Week 25 if dialysis occurred within 5 days prior to the first crovalimab administration or prior to the end date of the primary treatment period, respectively. The percentage of participants who required dialysis at baseline and Week 25 has been reported here. Percentages have been rounded off.

Time frame:
Baseline up to Week 25 (after 24 weeks on treatment)
Reported as:
Number · percentage of participants
Naive and Switch Cohorts: Percentage of Participants Requiring Dialysis at Baseline and at Week 25 Who Completed 24 Weeks of Treatment
percentage of participantsCrovalimab Naive CohortCrovalimab Switch Cohort
Baseline53.1 (36.45 to 69.13)0 (0.00 to 8.97)
Week 253.1 (0.55 to 15.74)0 (0.00 to 8.97)
SecondaryNaïve and Switch Cohorts: Percentage of Participants With Change From Baseline to Week 25 (After 24 Weeks on Treatment) on Dialysis Status (Yes/No)

Participants were considered as being on dialysis at baseline or at Week 25 if dialysis occurred within 5 days prior to the first crovalimab administration or prior to the end date of the primary treatment period, respectively. Participants who were on dialysis at any time point from baseline to Week 25 were classified as "Initiated dialysis at any time point ". Participants who remained dialysis-free throughout the primary treatment period were classified as "Remained dialysis free throughout". Participants who were on dialysis at Week 25 were classified as "Remained on dialysis". Participants who discontinued dialysis at Week 25 were classified as "Discontinued dialysis. Percentages have been rounded off.

Time frame:
From baseline up to Week 25
Reported as:
Number · percentage of participants
Naïve and Switch Cohorts: Percentage of Participants With Change From Baseline to Week 25 (After 24 Weeks on Treatment) on Dialysis Status (Yes/No)
percentage of participantsCrovalimab Naive CohortCrovalimab Switch Cohort
Initiated Dialysis at Any Timepoint12.50
Discontinued Dialysis53.10
Remained on Dialysis00
Remained Dialysis-free Throughout34.4100
SecondaryNaive and Switch Cohorts: Observed Values of Estimated Glomerular Filtration Rate (eGFR), as Calculated From Central Serum Creatinine

GFR is an index of kidney function that describes the flow rate of filtered fluid through the kidneys. It was categorized according to chronic kidney disease (CKD) staging criteria. eGFR was calculated using the creatinine-based bedside Schwartz equation for adolescents and 2009 CKD-Epidemiology Collaboration (EPI) creatinine equation for adults. Formula for creatinine-based bedside Schwartz equation was eGFR (milliliters per minute per 1.73 square meter \[mL/min/1.73 m\^2\])=0.413\*(height \[ht\]/serum creatinine \[sCr\]), if height is expressed in centimeters, or 41.3\*(ht/sCr), if height is expressed in meters, and formula for 2009 CKD-EPI creatinine equation was eGFR (mL/min/1.73 m\^2)= 141\*min(sCr /κ,1)\^α\*max(sCr/κ,1)\^ -1.209\*0.993\^AGE\[\*1.018 if female\]\[\*1.159 if black\], κ was 0.7 for females and 0.9 for males, α was -0.329 for females and -0.411 for males, min indicated the minimum of sCr/κ or 1, and max indicated the maximum of sCr/κ or 1.

Time frame:
Baseline, Weeks 2, 3, 4, 5, 7, 9, 13, 17, 21, and 25
Reported as:
Mean · mL/min/1.73 m^2
Naive and Switch Cohorts: Observed Values of Estimated Glomerular Filtration Rate (eGFR), as Calculated From Central Serum Creatinine
mL/min/1.73 m^2Crovalimab Naive CohortCrovalimab Switch Cohort
Baseline22.11 ± 16.4267.36 ± 32.73
Week 228.32 ± 22.3168.32 ± 32.42
Week 334.75 ± 26.6365.68 ± 33.38
Week 447.16 ± 31.8766.31 ± 33.18
Week 550.59 ± 30.7966.06 ± 33.07
Week 754.93 ± 31.7267.12 ± 32.53
Week 951.66 ± 31.9867.55 ± 30.7
Week 1354.88 ± 30.3469.25 ± 29.3
Week 1754.73 ± 30.8667.00 ± 29.77
Week 2157.82 ± 31.2468.71 ± 31.53
Week 2558.49 ± 28.1166.61 ± 30.54
SecondaryNaive and Switch Cohorts: Change From Baseline up to Week 25 in eGFR, as Calculated From Central Serum Creatinine

GFR is an index of kidney function that describes the flow rate of filtered fluid through the kidneys. It was categorized according to CKD staging criteria. eGFR was calculated using the creatinine-based bedside Schwartz equation for adolescents and 2009 CKD- EPI creatinine equation for adults. Formula for creatinine-based bedside Schwartz equation was eGFR (mL/min/1.73 m\^2)=0.413\*(ht/sCr), if height is expressed in centimeters, or 41.3\*(ht/sCr), if height is expressed in meters, and formula for 2009 CKD-EPI creatinine equation was eGFR (mL/min/1.73 m\^2)= 141\*min(sCr /κ,1)\^α\*max(sCr/κ,1)\^ -1.209\*0.993\^AGE\[\*1.018 if female\]\[\*1.159 if black\], κ was 0.7 for females and 0.9 for males, α was -0.329 for females and -0.411 for males, min indicated the minimum of sCr/κ or 1, and max indicated the maximum of sCr/κ or 1.

Time frame:
Baseline, Weeks 2, 3, 4, 5, 7, 9, 13, 17, 21, and 25
Reported as:
Mean · mL/min/1.73 m^2
Naive and Switch Cohorts: Change From Baseline up to Week 25 in eGFR, as Calculated From Central Serum Creatinine
mL/min/1.73 m^2Crovalimab Naive CohortCrovalimab Switch Cohort
Change at Week 26.3 ± 10.930.96 ± 5.17
Change at Week 311.87 ± 15.67-1.68 ± 7.45
Change at Week 422.72 ± 26.95-0.93 ± 6.94
Change at Week 524.7 ± 27.95-1.61 ± 7.43
Change at Week 730.26 ± 29.17-1.64 ± 7.93
Change at Week 927.64 ± 27.22-1.49 ± 9.46
Change at Week 1330.81 ± 24.75-2.42 ± 10.07
Change at Week 1730.97 ± 26.24-1.5 ± 9.33
Change at Week 2133.41 ± 25.94-0.33 ± 9.23
Change at Week 2533.9 ± 23.94-2.43 ± 9.36
SecondaryNaive and Switch Cohorts: Percentage of Participants With Change in Chronic Kidney Disease (CKD) Stage From Baseline to Week 25, as Assessed Based on eGFR Calculated From Central Serum Creatinine

CKD stage assessed using eGFR, classified per National Kidney Foundation CKD staging criteria: grade 1 (≥90 mL/min/1.73 m²; normal or high), grade 2 (60-89 mL/min/1.73 m²; mildly decreased), grade 3a (45-59 mL/min/1.73 m²; mildly to moderately decreased), grade 3b (30-44 mL/min/1.73 m²; moderately to severely decreased), grade 4 (15-29 mL/min/1.73 m²; severely decreased), grade 5 (\<15 mL/min/1.73 m²; kidney failure). Change in CKD stage from baseline to Week 25, categorized as improved (participants who improved in CKD stage from baseline to Week 25 were based on number of participants who completed 24 weeks \& were not stage 1 at baseline), stable (no change), or worsened (CKD stage 1-4 at baseline) among participants who completed 24 weeks of treatment. Percentages rounded off.

Time frame:
Baseline up to Week 25 (after 24 weeks on treatment)
Reported as:
Number · percentage of participants
Naive and Switch Cohorts: Percentage of Participants With Change in Chronic Kidney Disease (CKD) Stage From Baseline to Week 25, as Assessed Based on eGFR Calculated From Central Serum Creatinine
percentage of participantsCrovalimab Naive CohortCrovalimab Switch Cohort
Improved in CKD Stage78.1 (61.25 to 88.98)17.2 (7.6 to 34.55)
Worsened in CKD Stage0 (0 to 16.82)13.5 (5.91 to 27.98)
Stable (no Change) in CKD Stage9.4 (3.24 to 24.22)71.8 (56.22 to 83.46)
SecondaryNaive and Switch Cohorts: Observed Value of Platelet Count
Time frame:
Baseline and Week 25
Reported as:
Mean · cells*10^9 per liter (cells*10^9/L)
Naive and Switch Cohorts: Observed Value of Platelet Count
cells*10^9 per liter (cells*10^9/L)Crovalimab Naive CohortCrovalimab Switch Cohort
Baseline171.5 ± 116.6246.5 ± 72.3
Week 25229.3 ± 65.4241.2 ± 67.7
SecondaryNaive and Switch Cohorts: Observed Value of Lactate Dehydrogenase (LDH)
Time frame:
Baseline and Week 25
Reported as:
Mean · units per liter (U/L)
Naive and Switch Cohorts: Observed Value of Lactate Dehydrogenase (LDH)
units per liter (U/L)Crovalimab Naive CohortCrovalimab Switch Cohort
Baseline392.1 ± 352.0134.1 ± 21.8
Week 25137.1 ± 35.8142.0 ± 44.5
SecondaryNaive and Switch Cohorts: Observed Value of Hemoglobin
Time frame:
Baseline and Week 25
Reported as:
Mean · grams per liter (g/L)
Naive and Switch Cohorts: Observed Value of Hemoglobin
grams per liter (g/L)Crovalimab Naive CohortCrovalimab Switch Cohort
Baseline92.3 ± 16.7141.4 ± 17.8
Week 25127.6 ± 17.5140.4 ± 15.1
SecondaryNaive and Switch Cohorts: Change From Baseline in Platelet Count at Week 25
Time frame:
Baseline and Week 25
Reported as:
Mean · cells*10^9/L
Naive and Switch Cohorts: Change From Baseline in Platelet Count at Week 25
cells*10^9/LCrovalimab Naive CohortCrovalimab Switch Cohort
Naive and Switch Cohorts: Change From Baseline in Platelet Count at Week 2557.9 ± 108-4.9 ± 38.4
SecondaryNaive and Switch Cohorts: Change From Baseline in LDH at Week 25
Time frame:
Baseline and Week 25
Reported as:
Mean · U/L
Naive and Switch Cohorts: Change From Baseline in LDH at Week 25
U/LCrovalimab Naive CohortCrovalimab Switch Cohort
Naive and Switch Cohorts: Change From Baseline in LDH at Week 25-211.6 ± 186.27.3 ± 40.4
SecondaryNaive and Switch Cohorts: Change From Baseline in Hemoglobin at Week 25
Time frame:
Baseline and Week 25
Reported as:
Mean · g/L
Naive and Switch Cohorts: Change From Baseline in Hemoglobin at Week 25
g/LCrovalimab Naive CohortCrovalimab Switch Cohort
Naive and Switch Cohorts: Change From Baseline in Hemoglobin at Week 2535 ± 18.9-1.7 ± 9.4
SecondaryNaive and Switch Cohorts: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 25

Fatigue was measured by the FACIT-Fatigue questionnaire in adult participants only (≥18 years at baseline). It consists of 13 items that assess fatigue using a 7-day recall period. Items are scored on a 0= 'Not at all' to 4= 'Very much so' response scale. Relevant items are reverse scored, and all items are summed to create total score where higher scores are indicative of better functioning (i.e., less fatigue). The FACIT-Fatigue total score ranges from 0 to 52, with higher scores representing less fatigue; therefore, an increase in score represents an improvement in fatigue. Only categories with non-zero values were reported.

Time frame:
Baseline, Weeks 1 (Day 1), 2, 5, 9, 17, and 25
Reported as:
Mean · scores on a scale
Naive and Switch Cohorts: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 25
scores on a scaleCrovalimab Naive CohortCrovalimab Switch Cohort
Baseline30.74 ± 14.6840.95 ± 8.35
Change at Week 24.01 ± 7.872.22 ± 4.46
Change at Week 56.06 ± 9.261.23 ± 5.37
Change at Week 97.49 ± 11.541.65 ± 5.96
Change at Week 178.68 ± 12.821.24 ± 5.93
Change at Week 258.36 ± 11.750.41 ± 8.76
SecondaryNaive Cohort: Percentage of Participants With Platelet Count ≥ LLN at Two Separate Assessments, Obtained at Least 4 Weeks Apart (Minimum of 26 Days), by Week 25 (After 24 Weeks on Treatment)

This event was confirmed at two separate assessments obtained at least 4 weeks (a minimum of 26 days) apart and any measurement in between. Percentages are rounded off.

Time frame:
Baseline up to Week 25 (after 24 weeks on treatment)
Reported as:
Number · percentage of participants
Naive Cohort: Percentage of Participants With Platelet Count ≥ LLN at Two Separate Assessments, Obtained at Least 4 Weeks Apart (Minimum of 26 Days), by Week 25 (After 24 Weeks on Treatment)
percentage of participantsCrovalimab Naive Cohort
Naive Cohort: Percentage of Participants With Platelet Count ≥ LLN at Two Separate Assessments, Obtained at Least 4 Weeks Apart (Minimum of 26 Days), by Week 25 (After 24 Weeks on Treatment)81.1 (65.8 to 90.52)
SecondaryNaive Cohort: Percentage of Participants With LDH ≤ Upper Limit of Normal (ULN) at Two Separate Assessments, Obtained at Least 4 Weeks Apart (Minimum of 26 Days), by Week 25 (After 24 Weeks on Treatment)

Percentages are rounded off.

Time frame:
From baseline through Week 25 (after 24 weeks on treatment)
Reported as:
Number · percentage of participants
Naive Cohort: Percentage of Participants With LDH ≤ Upper Limit of Normal (ULN) at Two Separate Assessments, Obtained at Least 4 Weeks Apart (Minimum of 26 Days), by Week 25 (After 24 Weeks on Treatment)
percentage of participantsCrovalimab Naive Cohort
Naive Cohort: Percentage of Participants With LDH ≤ Upper Limit of Normal (ULN) at Two Separate Assessments, Obtained at Least 4 Weeks Apart (Minimum of 26 Days), by Week 25 (After 24 Weeks on Treatment)83.8 (68.86 to 92.35)
SecondaryNaive Cohort: Percentage of Participants With ≥25% Decrease in Serum Creatinine From Baseline at Two Separate Assessments, Obtained at Least 4 Weeks Apart (Minimum of 26 Days), by Week 25 (After 24 Weeks on Treatment)

Percentages are rounded off.

Time frame:
Baseline up to Week 25 (after 24 weeks on treatment)
Reported as:
Number · percentage of participants
Naive Cohort: Percentage of Participants With ≥25% Decrease in Serum Creatinine From Baseline at Two Separate Assessments, Obtained at Least 4 Weeks Apart (Minimum of 26 Days), by Week 25 (After 24 Weeks on Treatment)
percentage of participantsCrovalimab Naive Cohort
Naive Cohort: Percentage of Participants With ≥25% Decrease in Serum Creatinine From Baseline at Two Separate Assessments, Obtained at Least 4 Weeks Apart (Minimum of 26 Days), by Week 25 (After 24 Weeks on Treatment)64.9 (48.76 to 78.17)
SecondaryNaive Cohort: Time to Complete Thrombotic Microangiopathy Response (cTMAr)

cTMAr was defined by meeting all of the following criteria at two separate assessments, obtained at least 4 weeks (a minimum of 26 days) apart, and any measurement in between: Platelet count ≥ LLN; LDH ≤ ULN; and ≥ 25% decrease in serum creatinine from baseline and \> ULN. Kaplan-Meier (K-M) method was used to estimate median time to cTMAr. Data for participants who did not reach cTMAr during the primary treatment period were censored at the date of their last visit when cTMAr was assessed during the primary treatment period or prior to the treatment discontinuation, whichever was earlier. Data for participants who received a prohibited therapy during the primary treatment period were censored at the date of the first received prohibited therapy during the primary treatment period or prior to the treatment discontinuation, whichever was earlier.

Time frame:
From baseline up to Week 25
Reported as:
Median · weeks
Naive Cohort: Time to Complete Thrombotic Microangiopathy Response (cTMAr)
weeksCrovalimab Naive Cohort
Naive Cohort: Time to Complete Thrombotic Microangiopathy Response (cTMAr)12.1 (6.3 to 16.0)
SecondaryNaive Cohort: Duration of cTMAr

cTMAr was defined by meeting following criteria at 2 separate assessments, obtained at least 4 weeks (minimum of 26 days) apart \& any measurement in between: Platelet count ≥ LLN; LDH ≤ ULN; \& ≥25% decrease in serum creatinine from baseline \& \> ULN. Duration of cTMAr was calculated as time from start of cTMAr to end of cTMAr. End of cTMAr was when all above-mentioned criteria were met during same visit \& confirmed at an assessment that took place at least 4 weeks (minimum of 26 days) later. K-M method was used to estimate median duration of cTMAr. Data for participants with no observed end of cTMAr at clinical cutoff date (CCOD) were censored at the date of their last visit when cTMAr was assessed before CCOD or before treatment discontinuation, whichever was earlier. Data for participants who received a prohibited therapy prior to the CCOD were censored at date of the first received prohibited therapy or prior to the treatment discontinuation, whichever was earlier.

Time frame:
From baseline up to primary CCOD (up to 207 weeks)
Reported as:
Median · weeks
Naive Cohort: Duration of cTMAr
weeksCrovalimab Naive Cohort
Naive Cohort: Duration of cTMArNA (NA to NA)
SecondaryNaive Cohort: Percentage of Participants With cTMAr Ongoing at Week 25

cTMAr at Week 25 was defined by meeting all of the three cTMAr criteria at Week 25: Platelet count ≥ LLN; LDH ≤ ULN; and ≥ 25% decrease in serum creatinine from baseline and \> ULN. Percentage has been rounded off.

Time frame:
At Week 25
Reported as:
Number · percentage of participants
Naive Cohort: Percentage of Participants With cTMAr Ongoing at Week 25
percentage of participantsCrovalimab Naive Cohort
Naive Cohort: Percentage of Participants With cTMAr Ongoing at Week 2554.1 (38.38 to 68.96)
SecondarySwitch Cohort: Percentage of Participants With Maintained Thrombotic Microangiopathy Control (mTMAc) From Baseline Through Week 25 (After 24 Weeks on Treatment)

mTMAc was considered not maintained if all of the following criteria were met during one of the visits between baseline and Week 25, and were confirmed at an assessment that took place at least 4 weeks (a minimum of 26 days) later: Platelet count \< LLN; LDH \> ULN; and 25% increase in serum creatinine from baseline and \> ULN.

Time frame:
From baseline through Week 25 (After 24 weeks on treatment)
Reported as:
Number · percentage of participants
Switch Cohort: Percentage of Participants With Maintained Thrombotic Microangiopathy Control (mTMAc) From Baseline Through Week 25 (After 24 Weeks on Treatment)
percentage of participantsCrovalimab Switch Cohort
Switch Cohort: Percentage of Participants With Maintained Thrombotic Microangiopathy Control (mTMAc) From Baseline Through Week 25 (After 24 Weeks on Treatment)100 (91.43 to 100)
SecondaryAll Cohorts: Number of Participants With AEs

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Time frame:
Up to approximately 8 years

Results for this outcome have not been posted.

SecondaryAll Cohorts: Number of Participants With Injection-Site Reactions, Infusion-Related Reactions, Hypersensitivity, Malignant Hypertension and Infections

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Infusion-related and injection-site reactions were adverse events that occured during or within 24 hours after crovalimab administration and were judged to be related to study drug infusion or injection.

Time frame:
Up to approximately 8 years

Results for this outcome have not been posted.

SecondaryAll Cohorts: Number of Participants With AE Leading to Study Drug Discontinuation

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Time frame:
Up to approximately 8 years

Results for this outcome have not been posted.

SecondarySwitch Cohort: Number of Participants With Clinical Manifestations of Drug-target-drug Complexes (DTDCs)

In this study, the risk of DTDC is relevant only to participants who might switch to crovalimab from eculizumab or ravulizumab treatment at study enrollment, and to participants who discontinued crovalimab and switch to eculizumab or ravulizumab. Type III hypersensitivity may occur due to the transient formation of DTDCs made of eculizumab or ravulizumab, crovalimab, and C5 in participants switching from eculizumab or ravulizumab to crovalimab.

Time frame:
Up to approximately 8 years

Results for this outcome have not been posted.

SecondaryAll Cohorts: Crovalimab Serum Concentration
Time frame:
Up to approximately 8 years

Results for this outcome have not been posted.

SecondaryAll Cohorts: Percentage of Participants With Anti-Drug Antibodies (ADAs) to Crovalimab

Participants will be considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following study drug exposure (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples is at least 4-fold greater than the titer of the baseline sample (treatment-enhanced ADA response).

Time frame:
Up to approximately 8 years

Results for this outcome have not been posted.

SecondaryAll Cohorts: Observed Value of Complement Activity (CH50) Over Time, as Measured by Liposome Immunoassay (LIA)
Time frame:
Up to approximately 8 years

Results for this outcome have not been posted.

SecondaryAll Cohorts: Change From Baseline in CH50 Over Time, as Measured by LIA
Time frame:
Up to approximately 8 years

Results for this outcome have not been posted.

SecondaryAll Cohorts: Observed Value of Free Complement Component 5 (C5) Concentrations in Crovalimab-treated Participants
Time frame:
Up to approximately 8 years

Results for this outcome have not been posted.

SecondaryAll Cohorts: Change From Baseline in Free C5 Concentrations Over Time in Crovalimab-treated Participants
Time frame:
Up to approximately 8 years

Results for this outcome have not been posted.

SecondaryAll Cohorts: Observed Value of Total C5 Concentrations in Crovalimab-treated Participants
Time frame:
Up to approximately 8 years

Results for this outcome have not been posted.

SecondaryAll Cohorts: Change From Baseline in Total C5 Concentrations in Crovalimab-treated Participants
Time frame:
Up to approximately 8 years

Results for this outcome have not been posted.

Adverse events

Collected over Up to approximately 207 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Crovalimab Naive Cohort3/41 (7.3%)14/41 (34.1%)33/41 (80.5%)
Crovalimab Switch Cohort0/41 (0%)10/41 (24.4%)39/41 (95.1%)
Crovalimab C5 SNP Cohort0/1 (0%)1/1 (100%)1/1 (100%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventCrovalimab Naive CohortCrovalimab Switch CohortCrovalimab C5 SNP Cohort
Castleman's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/410/411/1
Thrombotic microangiopathyBlood and lymphatic system disorders2/411/410/1
PneumoniaInfections and infestations2/412/410/1
Pyelonephritis acuteInfections and infestations0/412/410/1
Urinary tract infectionInfections and infestations2/412/410/1
Atypical haemolytic uraemic syndromeBlood and lymphatic system disorders1/410/410/1
Cardiac arrestCardiac disorders1/410/410/1
Cardiac failure congestiveCardiac disorders1/410/410/1
MyocarditisCardiac disorders1/410/410/1
Wellens' syndromeCardiac disorders1/410/410/1
Most frequent other events
Showing 10 of 48
Most frequent other events
EventCrovalimab Naive CohortCrovalimab Switch CohortCrovalimab C5 SNP Cohort
Nephrogenic anaemiaBlood and lymphatic system disorders1/411/411/1
Ear congestionEar and labyrinth disorders0/410/411/1
GastritisGastrointestinal disorders2/411/411/1
StomatitisGastrointestinal disorders0/410/411/1
PainGeneral disorders0/411/411/1
Hepatic enzyme increasedInvestigations1/410/411/1
White blood cell count decreasedInvestigations1/410/411/1
HyperglycaemiaMetabolism and nutrition disorders0/410/411/1
HyperuricaemiaMetabolism and nutrition disorders0/410/411/1
DysgeusiaNervous system disorders0/410/411/1

Baseline characteristics

All participants population included all enrolled participants in the study.

Age, Continuous
Age, Continuous(years)Crovalimab Naive CohortCrovalimab Switch CohortCrovalimab C5 SNP CohortTotal
Mean37.7 ± 13.535.6 ± 16.755.0 ± NA36.9 ± 15.2
Sex: Female, Male
Sex: Female, Male(Participants)Crovalimab Naive CohortCrovalimab Switch CohortCrovalimab C5 SNP CohortTotal
Female2427051
Male1714132
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Crovalimab Naive CohortCrovalimab Switch CohortCrovalimab C5 SNP CohortTotal
Hispanic or Latino1211023
Not Hispanic or Latino2327151
Unknown or Not Reported6309
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Crovalimab Naive CohortCrovalimab Switch CohortCrovalimab C5 SNP CohortTotal
American Indian or Alaska Native2002
Asian120113
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White2137058
More than one race1102
Unknown or Not Reported5308
08

Study locations

41 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Oct 2025, 47 months.

Results were first posted in Oct 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2021
First posted
Apr 27, 2021
StartActual
Oct 22, 2021
Primary completionActual
Oct 9, 2025
CompletionEst.
Aug 20, 2029
Results first posted
Oct 30, 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 30, 2026
Sites
1 site removed
Show 1 removed
  • Medanta-The Medicity · Gurgaon, India
Oct 30, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedNaive Cohort: Percentage of Participants withWith Complete ThormboticThrombotic Microangiopathy Response (cTMAr) Anytime From Baseline to Week 25Time frame: Baseline up to Week 25 (after 24 weeks on treatment)
Oct 30, 2026
Documents
Secondary outcomes
12 edited, 18 added, 14 more
What changed in the outcomes
  • EditedNaive and Switch Cohorts: Percentage of Participants withWith Change from Baseline in Chronic Kidney Disease (CKD) Stage From Baseline to Week 25, as Assessed Based on eGFR Calculated From Central Serum CreatinineTime frame: Baseline up to Week 25 (after 24 weeks on treatment)
  • EditedNaive and Switch Cohorts: Observed Value inof Platelet CountTime frame: Baseline up to Week 25 (after 24 weeks on treatment) → Baseline and Week 25
  • EditedNaive and Switch Cohorts: Observed Value inof Lactate Dehydrogenase (LDH)Time frame: Baseline up to Week 25 (after 24 weeks on treatment) → Baseline and Week 25
  • EditedNaive and Switch Cohorts: Observed Value inof HemoglobinTime frame: Baseline up to Week 25 (after 24 weeks on treatment) → Baseline and Week 25
  • EditedNaive and Switch Cohorts: Change fromFrom Baseline in Platelet Count at Week 25Time frame: Baseline up to Week 25 (after 24 weeks on treatment) → Baseline and Week 25
  • EditedNaive and Switch Cohorts: Change fromFrom Baseline in Hemoglobin at Week 25Time frame: Baseline up to Week 25 (after 24 weeks on treatment) → Baseline and Week 25
  • EditedSwitch Cohort: Percentage of Participants withWith Maintained Thrombotic Microangiopathy Control (mTMAc) From Baseline Through Week 25 (Switch Cohort onlyAfter 24 Weeks on Treatment)Time frame: Baseline up to Week 25 (after 24 weeks on treatment) → From baseline through Week 25 (After 24 weeks on treatment)
  • EditedPercentageAll Cohorts: Number of Participants with Adverse Events (With AEs)Time frame: Up to 8 years → Up to approximately 8 years
  • EditedPercentageAll Cohorts: Number of Participants withWith Injection-Site Reactions, Infusion-Related Reactions, Hypersensitivity, Malignant Hypertension (Including Malignant Renal Hypertension) and Infections (Including Meningococcal Meningitis)Time frame: Up to 8 years → Up to approximately 8 years
  • EditedAll Cohorts: Number of Participants with AEsWith AE Leading to Study Drug DiscontinuationTime frame: Up to 8 years → Up to approximately 8 years
  • EditedPercentageSwitch Cohort: Number of Participants withWith Clinical Manifestations of Drug-Targettarget-Drug Complexdrug Complexes (DTDCDTDCs) Formation Amongst Those Participants who Switched to Crovalimab Treatment From Eculizumab Treatment or Ravulizumab TreatmentTime frame: Up to Week 25 → Up to approximately 8 years
  • EditedAll Cohorts: Percentage of Participants withWith Anti-CrovalimabDrug Antibodies (ADAs) to CrovalimabTime frame: Up to 8 years → Up to approximately 8 years
  • AddedNaive and Switch Cohorts: Percentage of Participants Requiring Dialysis at Baseline and at Week 25 Who Completed 24 Weeks of TreatmentTime frame: Baseline up to Week 25 (after 24 weeks on treatment)
  • AddedNaïve and Switch Cohorts: Percentage of Participants With Change From Baseline to Week 25 (After 24 Weeks on Treatment) on Dialysis Status (Yes/No)Time frame: From baseline up to Week 25
  • AddedNaive and Switch Cohorts: Observed Values of Estimated Glomerular Filtration Rate (eGFR), as Calculated From Central Serum CreatinineTime frame: Baseline, Weeks 2, 3, 4, 5, 7, 9, 13, 17, 21, and 25
  • AddedNaive and Switch Cohorts: Change From Baseline up to Week 25 in eGFR, as Calculated From Central Serum CreatinineTime frame: Baseline, Weeks 2, 3, 4, 5, 7, 9, 13, 17, 21, and 25
  • AddedNaive and Switch Cohorts: Change From Baseline in LDH at Week 25Time frame: Baseline and Week 25
  • AddedNaive and Switch Cohorts: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 25Time frame: Baseline, Weeks 1 (Day 1), 2, 5, 9, 17, and 25
  • AddedNaive Cohort: Percentage of Participants With Platelet Count ≥ LLN at Two Separate Assessments, Obtained at Least 4 Weeks Apart (Minimum of 26 Days), by Week 25 (After 24 Weeks on Treatment)Time frame: Baseline up to Week 25 (after 24 weeks on treatment)
  • AddedNaive Cohort: Percentage of Participants With LDH ≤ Upper Limit of Normal (ULN) at Two Separate Assessments, Obtained at Least 4 Weeks Apart (Minimum of 26 Days), by Week 25 (After 24 Weeks on Treatment)Time frame: From baseline through Week 25 (after 24 weeks on treatment)
  • AddedNaive Cohort: Percentage of Participants With ≥25% Decrease in Serum Creatinine From Baseline at Two Separate Assessments, Obtained at Least 4 Weeks Apart (Minimum of 26 Days), by Week 25 (After 24 Weeks on Treatment)Time frame: Baseline up to Week 25 (after 24 weeks on treatment)
  • AddedNaive Cohort: Time to Complete Thrombotic Microangiopathy Response (cTMAr)Time frame: From baseline up to Week 25
  • AddedNaive Cohort: Duration of cTMArTime frame: From baseline up to primary CCOD (up to 207 weeks)
  • AddedNaive Cohort: Percentage of Participants With cTMAr Ongoing at Week 25Time frame: At Week 25
  • AddedAll Cohorts: Crovalimab Serum ConcentrationTime frame: Up to approximately 8 years
  • AddedAll Cohorts: Observed Value of Complement Activity (CH50) Over Time, as Measured by Liposome Immunoassay (LIA)Time frame: Up to approximately 8 years
  • AddedAll Cohorts: Change From Baseline in CH50 Over Time, as Measured by LIATime frame: Up to approximately 8 years
  • AddedAll Cohorts: Observed Value of Free Complement Component 5 (C5) Concentrations in Crovalimab-treated ParticipantsTime frame: Up to approximately 8 years
  • AddedAll Cohorts: Change From Baseline in Free C5 Concentrations Over Time in Crovalimab-treated ParticipantsTime frame: Up to approximately 8 years
  • AddedAll Cohorts: Observed Value of Total C5 Concentrations in Crovalimab-treated ParticipantsTime frame: Up to approximately 8 years
  • …and 14 more, on the record history on ClinicalTrials.gov ↗
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Results posted
    1 site removed
    Show 1 removed
    • Medanta-The Medicity · Gurgaon, India
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedNaive Cohort: Percentage of Participants withWith Complete ThormboticThrombotic Microangiopathy Response (cTMAr) Anytime From Baseline to Week 25Time frame: Baseline up to Week 25 (after 24 weeks on treatment)
    Secondary outcomes 12 edited, 18 added, 14 more
    What changed in the outcomes
    • EditedNaive and Switch Cohorts: Percentage of Participants withWith Change from Baseline in Chronic Kidney Disease (CKD) Stage From Baseline to Week 25, as Assessed Based on eGFR Calculated From Central Serum CreatinineTime frame: Baseline up to Week 25 (after 24 weeks on treatment)
    • EditedNaive and Switch Cohorts: Observed Value inof Platelet CountTime frame: Baseline up to Week 25 (after 24 weeks on treatment) → Baseline and Week 25
    • EditedNaive and Switch Cohorts: Observed Value inof Lactate Dehydrogenase (LDH)Time frame: Baseline up to Week 25 (after 24 weeks on treatment) → Baseline and Week 25
    • EditedNaive and Switch Cohorts: Observed Value inof HemoglobinTime frame: Baseline up to Week 25 (after 24 weeks on treatment) → Baseline and Week 25
    • EditedNaive and Switch Cohorts: Change fromFrom Baseline in Platelet Count at Week 25Time frame: Baseline up to Week 25 (after 24 weeks on treatment) → Baseline and Week 25
    • EditedNaive and Switch Cohorts: Change fromFrom Baseline in Hemoglobin at Week 25Time frame: Baseline up to Week 25 (after 24 weeks on treatment) → Baseline and Week 25
    • EditedSwitch Cohort: Percentage of Participants withWith Maintained Thrombotic Microangiopathy Control (mTMAc) From Baseline Through Week 25 (Switch Cohort onlyAfter 24 Weeks on Treatment)Time frame: Baseline up to Week 25 (after 24 weeks on treatment) → From baseline through Week 25 (After 24 weeks on treatment)
    • EditedPercentageAll Cohorts: Number of Participants with Adverse Events (With AEs)Time frame: Up to 8 years → Up to approximately 8 years
    • EditedPercentageAll Cohorts: Number of Participants withWith Injection-Site Reactions, Infusion-Related Reactions, Hypersensitivity, Malignant Hypertension (Including Malignant Renal Hypertension) and Infections (Including Meningococcal Meningitis)Time frame: Up to 8 years → Up to approximately 8 years
    • EditedAll Cohorts: Number of Participants with AEsWith AE Leading to Study Drug DiscontinuationTime frame: Up to 8 years → Up to approximately 8 years
    • EditedPercentageSwitch Cohort: Number of Participants withWith Clinical Manifestations of Drug-Targettarget-Drug Complexdrug Complexes (DTDCDTDCs) Formation Amongst Those Participants who Switched to Crovalimab Treatment From Eculizumab Treatment or Ravulizumab TreatmentTime frame: Up to Week 25 → Up to approximately 8 years
    • EditedAll Cohorts: Percentage of Participants withWith Anti-CrovalimabDrug Antibodies (ADAs) to CrovalimabTime frame: Up to 8 years → Up to approximately 8 years
    • AddedNaive and Switch Cohorts: Percentage of Participants Requiring Dialysis at Baseline and at Week 25 Who Completed 24 Weeks of TreatmentTime frame: Baseline up to Week 25 (after 24 weeks on treatment)
    • AddedNaïve and Switch Cohorts: Percentage of Participants With Change From Baseline to Week 25 (After 24 Weeks on Treatment) on Dialysis Status (Yes/No)Time frame: From baseline up to Week 25
    • AddedNaive and Switch Cohorts: Observed Values of Estimated Glomerular Filtration Rate (eGFR), as Calculated From Central Serum CreatinineTime frame: Baseline, Weeks 2, 3, 4, 5, 7, 9, 13, 17, 21, and 25
    • AddedNaive and Switch Cohorts: Change From Baseline up to Week 25 in eGFR, as Calculated From Central Serum CreatinineTime frame: Baseline, Weeks 2, 3, 4, 5, 7, 9, 13, 17, 21, and 25
    • AddedNaive and Switch Cohorts: Change From Baseline in LDH at Week 25Time frame: Baseline and Week 25
    • AddedNaive and Switch Cohorts: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 25Time frame: Baseline, Weeks 1 (Day 1), 2, 5, 9, 17, and 25
    • AddedNaive Cohort: Percentage of Participants With Platelet Count ≥ LLN at Two Separate Assessments, Obtained at Least 4 Weeks Apart (Minimum of 26 Days), by Week 25 (After 24 Weeks on Treatment)Time frame: Baseline up to Week 25 (after 24 weeks on treatment)
    • AddedNaive Cohort: Percentage of Participants With LDH ≤ Upper Limit of Normal (ULN) at Two Separate Assessments, Obtained at Least 4 Weeks Apart (Minimum of 26 Days), by Week 25 (After 24 Weeks on Treatment)Time frame: From baseline through Week 25 (after 24 weeks on treatment)
    • AddedNaive Cohort: Percentage of Participants With ≥25% Decrease in Serum Creatinine From Baseline at Two Separate Assessments, Obtained at Least 4 Weeks Apart (Minimum of 26 Days), by Week 25 (After 24 Weeks on Treatment)Time frame: Baseline up to Week 25 (after 24 weeks on treatment)
    • AddedNaive Cohort: Time to Complete Thrombotic Microangiopathy Response (cTMAr)Time frame: From baseline up to Week 25
    • AddedNaive Cohort: Duration of cTMArTime frame: From baseline up to primary CCOD (up to 207 weeks)
    • AddedNaive Cohort: Percentage of Participants With cTMAr Ongoing at Week 25Time frame: At Week 25
    • AddedAll Cohorts: Crovalimab Serum ConcentrationTime frame: Up to approximately 8 years
    • AddedAll Cohorts: Observed Value of Complement Activity (CH50) Over Time, as Measured by Liposome Immunoassay (LIA)Time frame: Up to approximately 8 years
    • AddedAll Cohorts: Change From Baseline in CH50 Over Time, as Measured by LIATime frame: Up to approximately 8 years
    • AddedAll Cohorts: Observed Value of Free Complement Component 5 (C5) Concentrations in Crovalimab-treated ParticipantsTime frame: Up to approximately 8 years
    • AddedAll Cohorts: Change From Baseline in Free C5 Concentrations Over Time in Crovalimab-treated ParticipantsTime frame: Up to approximately 8 years
    • AddedAll Cohorts: Observed Value of Total C5 Concentrations in Crovalimab-treated ParticipantsTime frame: Up to approximately 8 years
    • …and 14 more, on the record history on ClinicalTrials.gov ↗
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04861259
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Apr 27, 2021
Start date
Oct 22, 2021
Primary completion
Oct 9, 2025
Completion
Aug 20, 2029 (estimated)
Results posted
Oct 30, 2026
Last update
Oct 30, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Crovalimab

Start the discussion